Philips Spectral CT 7500 RT, world’s first spectral 4DCT respiratory-gated imaging receives FDA 510(k) clearance

November 12, 2024

Designed specifically for use in radiation oncology, new Spectral CT 7500 RT enables personalized radiation therapy planning to deliver better care for more cancer patients

Amsterdam, the Netherlands – (NYSE: PHG, AEX: PHIA), a global leader in health technology, today announced a major advance in radiation oncology with 510(k) clearance from the US Food and Drug Administration (FDA) for its new detector-based spectral computed tomography (CT) radiotherapy solution. Philips marks the next step in personalized cancer care by integrating the unique tumor visualization and tissue characterization capabilities of spectral CT into cancer treatment and planning. Radiation oncologists can now precisely target radiation therapy to the specific physiological characteristics of a patient's tumor, minimizing damage to healthy surrounding tissue and reducing potential unwanted side effects.

Spectral CT 7500 RT revolutionizes radiation oncology imaging by combining true conventional and spectral CT capabilities in a single scan, seamlessly integrating into existing clinical workflows. As the first radiation therapy CT scanner to offer respiratory-gated spectral imaging, radiation oncologists have all the benefits of 4D conventional CT, and can also now apply the improved visualization and quantification of spectral CT. This latest innovation from Philips benefits radiotherapy departments by reducing the costs of additional scans while enhancing accuracy and enabling more effective treatment plans for a greater number of cancer patients.

“Tumor delineation, beam attenuation, and respiratory motion are critical factors in radiotherapy planning. The spectral information provided by Spectral CT 7500 RT enhances tissue characterization, enabling wider access to highly personalized and precisely targeted treatment for more patients without adding extra steps to current radiotherapy workflows,” said Dan Xu, Global Business Leader of CT at Philips.

Spectral CT has been shown to reduce proton stopping-power ratio (SPR) error by more than 50% compared to conventional CT, improving the accuracy of radiation treatment and sparing healthy tissue [1]. Philips Spectral CT 7500 RT acquires both true conventional CT and spectral CT information in a single scan. It can automatically create the SPR map and direct electron density (ED) results with less than 1% deviation [1] to enhance both the dose calculation and accuracy of radiotherapy planning.

"The Spectral CT system provides us with several capabilities that conventional CT does not have. It can provide electron density and effective atomic number results, which we can convert to the proton stopping-power ratio. And published data shows that the stopping power ratio obtained in this way has fewer uncertainties compared to regular calibration curves, thereby reducing the uncertainty margins during treatment planning," said Dr. Zhong Su, Physics Director, Department of Radiation Oncology at the University of Arkansas for Medical Sciences (UAMS) Medical Center (Arkansas, USA).

over the past four decades, helping physicians make confident and precise diagnoses to deliver better care for more people. The company is a recognized leader in spectral CT with its ‘always-on’ detector-based technology, providing spectral CT solutions across a wide range of clinical areas including cardiology, oncology, neurology, musculoskeletal, and pediatrics. For more information, visit .

[1] Longarino FK, Kowalewski A, Tessonnier T, et al. Potential of a Second-Generation Dual-Layer Spectral CT for Dose Calculation in Particle Therapy Treatment Planning. Front Oncol. 2022;12. doi:10.3389/fonc.2022.853495

For further information, please contact:

Kathy O’Reilly

Philips Global External Relations

Tel.:

E-mail:

About Royal Philips

Royal Philips (NYSE: PHG, AEX: PHIA) is a leading health technology company focused on improving people's health and well-being through meaningful innovation. Philips’ patient- and people-centric innovation leverages advanced technology and deep clinical and consumer insights to deliver personal health solutions for consumers and professional health solutions for healthcare providers and their patients in the hospital and the home. Headquartered in the Netherlands, the company is a leader in diagnostic imaging, ultrasound, image-guided therapy, monitoring, and enterprise informatics, as well as in personal health. Philips generated 2023 sales of EUR 18.2 billion and employs approximately 69,300 employees with sales and services in more than 100 countries. News about Philips can be found at .

Attachments